Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Author(s):
Kroger, N.; Iacobelli, S.; Franke, G.N.; Platzbecker, U.; Uddin, R.; Hubel, K.; Scheid, C.; Weber, T.; Robin, M.; Stelljes, M.; Afanasyev, B.; Heim, D.; Deliliers, G.L.; Onida, F.; Dreger, P.; Pini, M.; Guidi, S.; Volin, L.; Gunther, A.; Bethge, W.; Poire, X.; Kobbe, G.; Os, M. van; Brand, R. (0000-0002-9596-4579); Witte, T. de
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-07-01
Language
English
Is part of
Journal of Clinical Oncology (2017), Vol. 35, no. 19, p. 2157-+
